Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
AIFM1
REST API REST API
Homo sapiens
AIFM1 is differentially expressed in 254 experiments: 104 organism parts: kidney, liver, ... (102 more);, 196 disease states: normal, adenocarcinoma, ... (194 more);, 75 cell types 352 cell lines 31 compound treatments and 65 other conditions.
Synonyms AIF, PDCD8
Orthologs Aifm1 (Rattus norvegicus)   Aifm1 (Mus musculus)   AIFM1 (Bos taurus)   AIFM1 (Gallus gallus)   ENSCING00000005922 (Ciona intestinalis)   pdcd8 (Danio rerio)   AIF (Drosophila melanogaster)   aifm1 (Xenopus laevis)   AIFM1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, oxidoreductase activity, DNA binding, protein binding, mitochondrial inner membrane, cytoplasm, DNA damage response, signal transduction resulting in induction of apoptosis, cell redox homeostasis, membrane, mitochondrial intermembrane space, activation of caspase activity, soluble fraction, microsome, nucleus, electron carrier activity, perinuclear region of cytoplasm, DNA fragmentation involved in apoptotic nuclear change, neuron apoptosis, mitochondrion, apoptosis in response to endoplasmic reticulum stress, oxidation-reduction process, flavin adenine dinucleotide binding
InterPro Term FAD_pyr_nucl-diS_OxRdtase, Pyr_nucl-diS_OxRdtase_FAD/NAD, Pyr_OxRdtase_NAD-bd_dom
UniProt Accession O95831, Q1L6K4, Q1L6K6, Q2QKE4, E9PMQ8, E9PRR0, E9PMA0
Gene-Disease Assocation COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 6; COXPD6
Search EB-eye ENSG00000156709
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-MEXP-433, E-GEOD-3526, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (39 experiments)

Factor Value U/D Experiments
SW480
3
E-MEXP-1014, E-GEOD-2509, E-GEOD-18005
primary culture
2
E-GEOD-2450, E-GEOD-1657
MCF7
2
E-GEOD-5258, E-MTAB-37
A549
2
E-GEOD-3202, E-GEOD-6013
BT20
2
E-MTAB-37, E-MTAB-62
PC3
2
E-MEXP-2034, E-GEOD-5258
346 more value(s).


Cell type

studied in E-GEOD-360, E-GEOD-13909, E-GEOD-20677, E-GEOD-13987, E-TABM-34, ... (39 experiments)

Factor Value U/D Experiments
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
PTCL
1
E-GEOD-19069
osteoblast
1
E-MEXP-1216
adult native RPE from 89 y.o. donor
1
E-GEOD-18811
articular cartilage
1
E-MEXP-2488
BDCA3+ dendritic cell
1
E-TABM-34
69 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (51 experiments)

Factor Value U/D Experiments
cervical carcinoma
3
E-MTAB-62, E-MEXP-1331, E-MTAB-37
colon carcinoma
3
E-MTAB-62, E-GEOD-3726, E-MTAB-37
lung adenocarcinoma
3
E-MEXP-231, E-GEOD-2514, E-MTAB-62
prostate carcinoma
3
E-MEXP-2034, E-MTAB-62, E-GEOD-96
Burkitt's lymphoma
2
E-MTAB-37, E-GEOD-96
melanoma
2
E-MTAB-62, E-MTAB-37
190 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-6907, E-TABM-782, E-GEOD-5824, E-GEOD-3720, ... (17 experiments)

Factor Value U/D Experiments
control
2
E-GEOD-4006, E-GEOD-3284
lipopolysaccharide
2
E-TABM-868, E-GEOD-3720
none
3
4
E-MEXP-1230, E-GEOD-5824, E-TABM-868, E-GEOD-412, E-MEXP-1601, ... (7 experiments)
4,5-dianilinophthalimide
1
1
E-GEOD-5258
NaOH
1
E-MEXP-2590
unknown
1
E-GEOD-7307
25 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
69
1
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-17189, E-GEOD-6710, E-GEOD-21374, ... (7 experiments)

Clinical treatment
studied in E-GEOD-5377, E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-MEXP-958, ... (6 experiments)

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-2509, E-GEOD-22148, E-TABM-147, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MEXP-1482, E-GEOD-7578, E-MEXP-2340

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-321, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, ... (11 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-2748

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-2466, E-GEOD-1926, E-MEXP-2069, ... (30 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12254, E-MEXP-561, E-GEOD-980 ... (5 experiments)

Injury
studied in E-GEOD-19743

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460 ... (5 experiments)

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445

Replicate
studied in E-GEOD-10797

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-1676, E-MEXP-1857, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400 ... (5 experiments)

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276, E-GEOD-2748

Treatment
studied in E-MEXP-973, E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Vehicle
studied in E-GEOD-5258

Processing time: 0.314 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM